Valneva's Stock Plummets as Analyst Downgrade Overshadows Strong Quarterly Sales

A stark divergence between operational performance and market sentiment is defining the current chapter for French vaccine specialist Valneva. While analysts project a robust first-quarter revenue beat, the company's shares are in freefall, pressured by a critical downgrade from Goldman Sachs and mounting pipeline uncertainties.

The investment bank slashed its rating on Valneva to "Sell" from "Neutral" on Wednesday, simultaneously cutting its price target to €2.15 from €3.25. This new target sits below the stock's current trading level, signaling expectations for further declines. The shares fell to €2.41 following the news, hovering just above a new annual low and marking a loss of over 37% since the start of the year.

This bearish stance stems from two significant clinical and commercial setbacks. A primary catalyst for the reassessment was Valneva's withdrawal of its U.S. application for the Chikungunya vaccine Ixchiq after the FDA placed it on hold. The removal of this anticipated near-term revenue driver has left a notable gap in growth expectations. Concurrently, doubts have intensified around the Lyme disease vaccine candidate VLA15, developed with Pfizer.

The pivotal Phase 3 VALOR study for VLA15 reported a vaccine efficacy of 73.2%, yet failed to meet its primary endpoint due to a lower-than-anticipated number of disease cases in the trial population. Goldman Sachs analysts see no clear precedent for regulatory approval under these conditions and question whether advisory committees would recommend its use. Valneva's management is now pinning its hopes on presenting the totality of clinical data to regulators, arguing a modified analysis shows slightly higher protection and highlighting the significant unmet medical need in the Northern Hemisphere.

Should investors sell immediately? Or is it worth buying Valneva?

Amid this pipeline turmoil, the company's established commercial business is providing a financial lifeline. Analysts at Guggenheim forecast first-quarter 2026 revenue of €49.1 million, notably above the market consensus of around €45 million. This strength is driven by sustained demand for the travel vaccines Ixiaro and Dukoral, bolstered by ongoing global travel activity. For the full year 2026, management maintains its revenue guidance of between €155 million and €170 million.

Financially, the company closed the 2025 fiscal year with an adjusted EBITDA loss of €59.4 million, weighed down by higher production costs, batch failures, and inventory write-downs. Despite these pressures, the core products demonstrate solid margins, with Ixiaro achieving a gross margin of nearly 60% and Dukoral around 33%.

Looking further ahead, Valneva continues to advance its tetravalent Shigella vaccine candidate, with Phase 2 results expected later in 2026. However, this longer-term project does little to alleviate immediate concerns over cash burn from ongoing R&D and the vanished U.S. Chikungunya revenue stream.

Valneva at a turning point? This analysis reveals what investors need to know now.

Trading with an annualized volatility exceeding 100% and an RSI of 62.5, Valneva's stock remains a highly speculative instrument, currently positioned just 4% above its 52-week low. The company's fate now hinges on fraught regulatory negotiations for its Lyme vaccine, as its solid travel vaccine business offers little more than consolation to investors awaiting a decisive growth catalyst.

Ad

Valneva Stock: New Analysis - 23 April

Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Valneva analysis...

en | FR0004056851 | VALNEVAS | boerse | 69238535 |